ABT-263 (Navitoclax)

Catalog No.S1001

ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Price Stock Quantity  
USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

ABT-263 (Navitoclax) Chemical Structure

ABT-263 (Navitoclax) Chemical Structure
Molecular Weight: 974.61

Validation & Quality Control

Cited by 36 publications:

13 customer reviews :

Quality Control & MSDS

Related Compound Libraries

ABT-263 (Navitoclax) is available in the following compound libraries:

Bcl-2 Inhibitors with Unique Features

  • Selective Bcl-2 Inhibitor

    ABT-199 (GDC-0199) Bcl-2-selective, Ki<0.01 nM.

  • Bcl-2 Inhibitor in Clinical Trial

    Obatoclax Mesylate (GX15-070) Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.

  • Newest Bcl-2 Family Activator

    BAM7 Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.

  • Classic Bcl-2 Inhibitor

    ABT-737 BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Product Information

  • Compare Bcl-2 Inhibitors
    Compare Bcl-2 Products
  • Research Area
  • Inhibition Profile

Product Description

Biological Activity

Description ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
A1 [1]
(Cell-free assay)
Mcl-1 [1]
(Cell-free assay)
IC50 <=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki) 354 nM(Ki) 550 nM(Ki)
In vitro ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
EoL-1-cellMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWTJR|UxRTBwMEC2Olkh|ryPMX;TRW5ITVJ?
MV-4-11MlSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoHyTWM2OD1yLkCxOVg3KM7:TR?=MV\TRW5ITVJ?
NKM-1Mnn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH;lfI1KSzVyPUCuNFE3QTlizszNNUDpe4NiW0GQR1XS
ML-2NWC5PIRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3nVUGlEPTB;MD6wNVk5OyEQvF2=M4TvTnNCVkeHUh?=
BV-173NYXrS5dqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PqNGlEPTB;MD6wNlMyPCEQvF2=M1Ozc3NCVkeHUh?=
RS4-11NHW0[IxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGfGTXpKSzVyPUCuNFI2QDdizszNNI\kWFFUSU6JRWK=
HL-60MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1XreWlEPTB;MD6wNlkxQCEQvF2=NIHJcoJUSU6JRWK=
KY821NETZRWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTBwMEK5O|Uh|ryPNXjjT3Z2W0GQR1XS
ECC10M{TBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTBwMEO3PVIh|ryPNV;zUmlKW0GQR1XS
NCI-H720NH;LZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTBwMESwNVEh|ryPNV6wUnAzW0GQR1XS
QIMR-WILNYSxfm95T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTBwMESyPFch|ryPNWrzRXg1W0GQR1XS
KG-1NXXvSmJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MofhTWM2OD1yLkC0OFg3KM7:TR?=NWX2fJozW0GQR1XS
TGWMlG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MonoTWM2OD1yLkC0OlM{KM7:TR?=MVzTRW5ITVJ?
ATN-1M1vafGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2\RPWlEPTB;MD6wOFc{OyEQvF2=NEf1Zo5USU6JRWK=
RH-18NX3RfGJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;1TWM2OD1yLkC2NFQ5KM7:TR?=MnrxV2FPT0WU
EW-18MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFu4boxKSzVyPUCuNFY5PDFizszNNHj3TFFUSU6JRWK=
NB17MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTBwMEexNlQh|ryPM1HsXXNCVkeHUh?=
SK-NEP-1MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH7GNYRKSzVyPUCuNFczOTNizszNMmDNV2FPT0WU
P12-ICHIKAWAM{PK[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXTwWXJxUUN3ME2wMlA4Pzd6IN88US=>NFvERmhUSU6JRWK=
KARPAS-45MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mke4TWM2OD1yLkC3PFE2KM7:TR?=NFi1b|FUSU6JRWK=
EW-3NUTx[2ZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NW\HepFHUUN3ME2wMlA5ODV|IN88US=>MoewV2FPT0WU
NB13Mk\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M33OS2lEPTB;MD6wPFIxOyEQvF2=M1PpTXNCVkeHUh?=
NCI-H209NWP6bI1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2WyPWlEPTB;MD6wPFcxPCEQvF2=Ml\zV2FPT0WU
NCI-H1092MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWjuZo1PUUN3ME2wMlExOjd3IN88US=>NFTv[ZNUSU6JRWK=
NH-12NED3VFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnKT|hKSzVyPUCuNVA4PDRizszNM3rE[XNCVkeHUh?=
697MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHGzXoZKSzVyPUCuNVA5OzlizszNMYjTRW5ITVJ?
KE-37NYXOVnE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2ruUWlEPTB;MD6xNVM4KM7:TR?=Mnr5V2FPT0WU
MOLT-4NWTQXIxTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NELl[mRKSzVyPUCuNVUyPjlizszNNVXkN2hpW0GQR1XS
CHP-134Mkj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnTqTWM2OD1yLkG2N|A3KM7:TR?=NYHqXXhIW0GQR1XS
D-283MEDM{LmU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjPTWM2OD1yLkG3Olg3KM7:TR?=MkPwV2FPT0WU
LU-135MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3hTWM2OD1yLkG4OVUzKM7:TR?=MWnTRW5ITVJ?
LU-134-ANGnlOI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkPRTWM2OD1yLkG4OlcyKM7:TR?=M2XCXHNCVkeHUh?=
EM-2NV\uO4d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTBwMUm5NVgh|ryPNFO1SmRUSU6JRWK=
LU-139NYr0[|dkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTBwMkC0PVgh|ryPNHXXflFUSU6JRWK=
ALL-POMknyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmHYTWM2OD1yLkKxPVg5KM7:TR?=NFWxcJpUSU6JRWK=
NB12MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTBwMkOxNVUh|ryPNXH6cJZNW0GQR1XS
KP-N-YNMlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTBwMkO1O|Mh|ryPM1PIdnNCVkeHUh?=
BENNI\I[pZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnrVTWM2OD1yLkKzPVY5KM7:TR?=M3XMenNCVkeHUh?=
HCC1569NXX3W4JET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTBwMkWxNFYh|ryPMVzTRW5ITVJ?
HuO9MlTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4SyemlEPTB;MD6yOlcyPSEQvF2=MkTJV2FPT0WU
WM-115NWX3PGQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnyxTWM2OD1yLkK3O|M5KM7:TR?=M4XQeHNCVkeHUh?=
CCRF-CEMMnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTBwM{O1Nlkh|ryPM3\LVnNCVkeHUh?=
IST-SL1MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIX1NIlKSzVyPUCuN|U{PDNizszNM3TkcHNCVkeHUh?=
BE-13MmjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlXCTWM2OD1yLkO2OFU6KM7:TR?=M3zUWHNCVkeHUh?=
COR-L88NHjtdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF3QcVBKSzVyPUCuN|Y2PCEQvF2=NILqVGFUSU6JRWK=
DOHH-2NHnwcm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPOSmpMUUN3ME2wMlQyODJ|IN88US=>NGXRSZJUSU6JRWK=
A704NVT2XmU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEf5eHlKSzVyPUCuOFI3PyEQvF2=MnfrV2FPT0WU
KNS-81-FDNUPCPWFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTBwNESwNVch|ryPNYrLTmxPW0GQR1XS
RPMI-8226NUL2VJpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYC3UGFuUUN3ME2wMlQ2PjV{IN88US=>MUnTRW5ITVJ?
TGBC24TKBM3PVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LHT2lEPTB;MD60OVc4QCEQvF2=NWjiW5ZZW0GQR1XS
NCI-H1304Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4TjdmlEPTB;MD60OlE2PyEQvF2=MknDV2FPT0WU
MOLT-13MlLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4OzfmlEPTB;MD60OlYyOyEQvF2=MUfTRW5ITVJ?
EW-22NXH1S2t3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1O2OWlEPTB;MD60OlY4OSEQvF2=MoTnV2FPT0WU
MS-1MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHHnSGhKSzVyPUCuOFY6OzNizszNMWjTRW5ITVJ?
RMG-INUHleIs3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\0bWlEPTB;MD60PVQ3PCEQvF2=MmPPV2FPT0WU
NTERA-S-cl-D1MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTBwNUCwNVkh|ryPMnfXV2FPT0WU
NCI-H1048NVHnV3BST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoPNTWM2OD1yLkWwPVU{KM7:TR?=MVnTRW5ITVJ?
SW1417NXmzS3BmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{GzSmlEPTB;MD61OVQ{QCEQvF2=MVrTRW5ITVJ?
DBM3LlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlriTWM2OD1yLkW3NFgh|ryPM1W2WXNCVkeHUh?=
MEG-01MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTBwNUizNkDPxE1?NUTkPWhnW0GQR1XS
EW-13NU\pO2pJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFf0TZlKSzVyPUCuOVg{PDFizszNM{TDO3NCVkeHUh?=
LAMA-84NVL5TIxJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mom1TWM2OD1yLkW5NlA4KM7:TR?=MmS4V2FPT0WU
J-RT3-T3-5Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTBwNkC4NFgh|ryPM3rZU3NCVkeHUh?=
MOLT-16MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWLCUZI3UUN3ME2wMlY2OjZ2IN88US=>MnfOV2FPT0WU
DU-4475M2DjRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYLscmpbUUN3ME2wMlY2PDJ5IN88US=>NVvhem5vW0GQR1XS
HAL-01Mn\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXy2U4RtUUN3ME2wMlczPTR7IN88US=>NH3w[IVUSU6JRWK=
RDMnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFX2S4lKSzVyPUCuO|U5QTlizszNNULRNXU2W0GQR1XS
OAW-28NXXWO5U6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlX3TWM2OD1yLke4N|ch|ryPM3vTXnNCVkeHUh?=
HCC38MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTBwOECxPUDPxE1?M1vuWXNCVkeHUh?=
NMC-G1MkW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVfJNnhZUUN3ME2wMlgyOTJzIN88US=>M{LFZ3NCVkeHUh?=
EW-16MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRTBwOEGzNlgh|ryPNFnyUI1USU6JRWK=
DU-145M1W4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4iyTGlEPTB;MD64PVkzOyEQvF2=M37rRnNCVkeHUh?=
HPAF-IIM2DCNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXvJR|UxRTBwOUK2Nlgh|ryPNVTLOGVHW0GQR1XS
A427NEfqdmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1jxVmlEPTB;MD65N|AzOiEQvF2=MlHCV2FPT0WU
PA-1NFjFR4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkW5TWM2OD1yLkm1OlQzKM7:TR?=MYPTRW5ITVJ?
OAW-42NYXCfG1iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmH5TWM2OD1yLkm2NVQ3KM7:TR?=M2XHeHNCVkeHUh?=
L-428MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTFwMEGyOUDPxE1?NXnxTpNDW0GQR1XS
COLO-824M2DOfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4PSVmlEPTB;MT6wNVcxQCEQvF2=NF\MO4lUSU6JRWK=
P30-OHKM3vK[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2\tXmlEPTB;MT6wOFY5QCEQvF2=NX7n[XZLW0GQR1XS
NCI-H2170MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1zxe2lEPTB;MT6wOlI{KM7:TR?=NU\RcZZbW0GQR1XS
HCC2998MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mme5TWM2OD1zLkC3NVM2KM7:TR?=M1nuU3NCVkeHUh?=
NB14Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH\ZPVJKSzVyPUGuNVM4PDhizszNNV\5V|F1W0GQR1XS
TGBC1TKBNHTEeIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1XrOGlEPTB;MT6xOFE2OiEQvF2=NXvHWms3W0GQR1XS
KP-N-YSMnLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG\idoFKSzVyPUGuNVYzOzZizszNM2TpOHNCVkeHUh?=
CAL-120MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXKNVRKSzVyPUGuNVY1OjlizszNNVW2cFVvW0GQR1XS
SBC-1MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFLkZWRKSzVyPUGuNVkxPTNizszNNXq3emlWW0GQR1XS
C32MlTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\xTWM2OD1zLkG5NFg5KM7:TR?=MkSyV2FPT0WU
HCC2157M3G1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTFwMUm0PVQh|ryPNX7zdYZrW0GQR1XS
COLO-792MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTFwMkCwO|Eh|ryPNFHxenRUSU6JRWK=
ES7NXTJUWFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{HNO2lEPTB;MT6yO|k2OSEQvF2=MWHTRW5ITVJ?
HELMoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2n2[GlEPTB;MT6zNVAzQSEQvF2=M3XRWXNCVkeHUh?=
ES4M4XZcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWPrW3BWUUN3ME2xMlM1QTl6IN88US=>NVjk[5hNW0GQR1XS
NCI-SNU-1MkX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWPJR|UxRTFwM{[1OVUh|ryPMof3V2FPT0WU
MDA-MB-415MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1ewWWlEPTB;MT6zPFg2KM7:TR?=NW[zfJd1W0GQR1XS
NCI-H2342MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHH[VlLUUN3ME2xMlQxOjZ7IN88US=>M1vMeXNCVkeHUh?=
NB69MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV7IcWM{UUN3ME2xMlQ3OjdzIN88US=>M4X5VnNCVkeHUh?=
D-247MGM1H5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlPFTWM2OD1zLkWxNVIzKM7:TR?=NYHHO|NDW0GQR1XS
SCC-4NEnyfHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlOxTWM2OD1zLkW5PFg4KM7:TR?=M{nNbnNCVkeHUh?=
HuH-7NF3IR3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4K4VGlEPTB;MT62O|I6OyEQvF2=MmjsV2FPT0WU
A388NXnPW5RmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmX0TWM2OD1zLk[4O|I1KM7:TR?=M{\PVnNCVkeHUh?=
Calu-3Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHvVbY9KSzVyPUGuO|A3QTdizszNMl\xV2FPT0WU
NCI-H1648MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3XmU2lEPTB;MT63NVQyQCEQvF2=NWPFWFBTW0GQR1XS
NCI-H2052MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlLhTWM2OD1zLkeyNlAyKM7:TR?=MX;TRW5ITVJ?
Ramos-2G6-4C10M1voXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4HycGlEPTB;MT63N|Y2PiEQvF2=NULBUWhyW0GQR1XS
DELMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3Tqc2lEPTB;MT63OFY6OiEQvF2=MkDFV2FPT0WU
SNU-423MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoDlTWM2OD1zLke4NVU4KM7:TR?=MV;TRW5ITVJ?
COR-L23NV65dJJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTFwN{m4O|Qh|ryPM2\JVXNCVkeHUh?=
OMC-1Mn;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2POcGlEPTB;MT64OlAyPiEQvF2=NYTVWIJKW0GQR1XS
EW-11MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4ryVmlEPTB;MT65OVY2PyEQvF2=M3e2c3NCVkeHUh?=
HSC-3M4HjTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmLkTWM2OD1zLkm2N|Y2KM7:TR?=MX;TRW5ITVJ?
MLMAMmjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPFTWM2OD1zLkm2Olc4KM7:TR?=NGPFdolUSU6JRWK=
RCM-1NEXtR3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIP5NG1KSzVyPUKuNFA{QTlizszNMXvTRW5ITVJ?
MFE-280NUPHZZZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHvTWM2OD1{LkCyPFQ5KM7:TR?=NVztO2o5W0GQR1XS
ES8MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXfMfYl[UUN3ME2yMlI2PDdzIN88US=>NWjITGY2W0GQR1XS
TE-11M2f2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkfNTWM2OD1{LkK5OFc{KM7:TR?=M33hS3NCVkeHUh?=
HuO-3N1NVLZWlhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVKybYx2UUN3ME2yMlQ5PzhizszNMXHTRW5ITVJ?
MHH-NB-11NUXQSGlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV7sOXhvUUN3ME2yMlUyOTV6IN88US=>MkCzV2FPT0WU
TGBC11TKBMknQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHrV[VJKSzVyPUKuOVc3QDFizszNNXLnZ2pTW0GQR1XS
HOP-92MkfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4W4bGlEPTB;Mj61PFc1OyEQvF2=M4XC[3NCVkeHUh?=
IGR-1MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTJwNkKwN|Uh|ryPNXTyeWJ7W0GQR1XS
GOTONFjTOWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFf6VmVKSzVyPUKuOlU{PzdizszNMVXTRW5ITVJ?
NCI-H1650NFHNTFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnPLTWM2OD1{LkeyNlE2KM7:TR?=MknkV2FPT0WU
NCI-H1581MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmi4TWM2OD1{Lke5OlgyKM7:TR?=MnvqV2FPT0WU
NCI-H2405Ml7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEOwT5FKSzVyPUKuPFI4QDJizszNNULqZWdPW0GQR1XS
U-118-MGMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{P2fWlEPTB;Mj65OlQ6OSEQvF2=NEThfJFUSU6JRWK=
DoTc2-4510MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXMSHJKSzVyPUOuNFE1OTdizszNNHPscndUSU6JRWK=
NCI-H596NH63fI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFHR[WlKSzVyPUOuNFQ6QTdizszNNX7Jc404W0GQR1XS
MPP-89M3Pj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PXT2lEPTB;Mz6wOVY3PiEQvF2=M4XTRXNCVkeHUh?=
GCIYMoqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1OzWGlEPTB;Mz6yNFQ6OSEQvF2=MXvTRW5ITVJ?
SW626MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NET1b3JKSzVyPUOuNlQ2PDNizszNM3TMUXNCVkeHUh?=
OCI-AML2NXqxfmFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmDuTWM2OD1|LkOxNlczKM7:TR?=MkH4V2FPT0WU
NBsusSRM{ixOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\wRWlEPTB;Mz6zOFk{QCEQvF2=NVm1ZnNkW0GQR1XS
AN3-CAMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{HiVmlEPTB;Mz60OFI{QCEQvF2=NYD3bZZ2W0GQR1XS
EFM-19NYLsdFhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPaTWM2OD1|LkS4N|M6KM7:TR?=NFL3ZYZUSU6JRWK=
RVH-421M4fnRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH:5UopKSzVyPUOuOVY5PzdizszNM1vzXXNCVkeHUh?=
5637NXT4Z2VxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTNwNkGxNFMh|ryPMoDBV2FPT0WU
PANC-08-13MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWfXWYh[UUN3ME2zMlY{PDd{IN88US=>MXjTRW5ITVJ?
H9NInTVWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWT6TmhZUUN3ME2zMlY4OTR2IN88US=>M2rsRnNCVkeHUh?=
KARPAS-299NW\JS3BwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFjFRYRKSzVyPUOuOlc{PjFizszNNHztW3JUSU6JRWK=
TE-5M{LHSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlTSTWM2OD1|LkewO|A6KM7:TR?=MXHTRW5ITVJ?
NOS-1NVfD[mR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;lZ2lEPTB;Mz63PVg{PCEQvF2=NWnWPJpbW0GQR1XS
HHMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUHmdXhVUUN3ME2zMlg{QDZ6IN88US=>M2TBV3NCVkeHUh?=
769-PMkHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDTO3NrUUN3ME2zMlg6PTFizszNM{PVeXNCVkeHUh?=
CHP-212M4T4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVn5NYF[UUN3ME2zMlkzPTR7IN88US=>MX7TRW5ITVJ?
NCI-H82MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1n4O2lEPTB;Mz65OVk{PiEQvF2=NUnLUXk6W0GQR1XS
Mo-TMoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jEPWlEPTB;ND6wOFMyOiEQvF2=NIn2PW9USU6JRWK=
BB65-RCCNEO0c|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{L0fmlEPTB;ND6wOFM6QSEQvF2=NELUOnpUSU6JRWK=
SW1990Mme1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnrPTWM2OD12LkC1PVA5KM7:TR?=M3:4SHNCVkeHUh?=
LK-2NGfUfI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MorkTWM2OD12LkGxNlk{KM7:TR?=Mkm3V2FPT0WU
ES5MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkHjTWM2OD12LkGzPVg2KM7:TR?=NEHIPYJUSU6JRWK=
JVM-3M3HVfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXToeVczUUN3ME20MlE5OjJ{IN88US=>NIDqd5NUSU6JRWK=
RPMI-7951MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUGzNWhKUUN3ME20MlIzPDF|IN88US=>NGWxPYhUSU6JRWK=
Calu-6NYfwRYdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlPrTWM2OD12LkK3PFgyKM7:TR?=NGPqVVJUSU6JRWK=
LC-2-adMmHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYPrd3NUUUN3ME20MlI6PTZ6IN88US=>Mmr4V2FPT0WU
SW954NFnwSJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXvRVos{UUN3ME20MlI6PjZizszNNYP4cXJlW0GQR1XS
H-EMC-SSM3rTdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\iTWM2OD12LkOxPFMyKM7:TR?=MUTTRW5ITVJ?
ES3NGfw[otIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLFeGY4UUN3ME20MlM2PDRzIN88US=>NUPFSm97W0GQR1XS
no-11NVfxOmMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\pTIpKSzVyPUSuN|U2PTRizszNMnXmV2FPT0WU
LAN-6Moq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVHFZZdPUUN3ME20MlQ2OTh7IN88US=>NH7jOG5USU6JRWK=
FTC-133MkTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHGTWM2OD12LkWzPVUh|ryPM2fBUnNCVkeHUh?=
8505CMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFvWO4NKSzVyPUSuOVQzOyEQvF2=MXjTRW5ITVJ?
SW620Mn34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTRwNUewOVch|ryPM3XSVXNCVkeHUh?=
BCPAPM4XkVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{npOmlEPTB;ND62N|Q5OSEQvF2=NYPQcGR[W0GQR1XS
SK-LU-1MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NU\6RZA6UUN3ME20MlY3ODh7IN88US=>NFzVe5JUSU6JRWK=
NCI-H1623NWWxe2t3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTRwN{CyNlgh|ryPNX7hd4gxW0GQR1XS
C2BBe1MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTRwN{SwNFgh|ryPMnO1V2FPT0WU
GP5dNFm3OpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGjIUXdKSzVyPUSuO|g{QDhizszNNYj3UFRpW0GQR1XS
NB6Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LvOmlEPTB;ND64OlIxPCEQvF2=NIi1dJBUSU6JRWK=
MDA-MB-157MnzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2fnNmlEPTB;ND64PFc3KM7:TR?=NWLwSm9CW0GQR1XS
UMC-11M1L2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlz2TWM2OD12Lki4PVY1KM7:TR?=MnroV2FPT0WU
HCC1419Ml:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTRwOUCwOlMh|ryPNX\HU2VCW0GQR1XS
NCI-H2029NUOzSJZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHX2dFBKSzVyPUSuPVQyQDVizszNM{nCOXNCVkeHUh?=
LXF-289M1LmSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTVwMEO3NVkh|ryPNXnTS5hOW0GQR1XS
KINGS-1MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGT2XXBKSzVyPUWuNFc4PDRizszNM{LoWHNCVkeHUh?=
HD-MY-ZMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1vLdWlEPTB;NT6yN|k3QSEQvF2=MlnaV2FPT0WU
ESS-1MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPzbY5KSzVyPUWuNlU2QTdizszNMofnV2FPT0WU
GI-1M3vLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGKweXVKSzVyPUWuNlc6OjZizszNMkTiV2FPT0WU
RPMI-2650NGjuXY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTVwM{[xOkDPxE1?MnTvV2FPT0WU
IA-LMNX\HSJJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NY[yXW02UUN3ME21MlM6QDdzIN88US=>NFfNdJpUSU6JRWK=
KP-4M2C0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX:1Xpp[UUN3ME21MlQ3OzN2IN88US=>NXnu[mhVW0GQR1XS
G-402M2nwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{PISGlEPTB;NT61NVg3PSEQvF2=MUnTRW5ITVJ?
OS-RC-2NEX6S41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUXMd4R7UUN3ME21MlUzPjB2IN88US=>MYDTRW5ITVJ?
NCI-H1155NFvkTJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHjFbmZKSzVyPUWuOVQ6PTVizszNM4Ta[XNCVkeHUh?=
OE19M4\hdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\QTWM2OD13Lk[4OlI1KM7:TR?=NXT4S5NDW0GQR1XS
U-2-OSNXq1ZWdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3HVlNKSzVyPUWuPFkxOTNizszNM2PTVXNCVkeHUh?=
SCC-15NEjoXJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17GfmlEPTB;NT65N|Y3OiEQvF2=Ml3WV2FPT0WU
NCI-H630NWnPWIlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\ROmlEPTB;NT65PVQxPCEQvF2=MVTTRW5ITVJ?
PFSK-1NVez[WZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\pNppjUUN3ME22MlA2OjV7IN88US=>NH3pWnRUSU6JRWK=
NCI-H1770NXjDbY9yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTZwMkC4O|Qh|ryPMomxV2FPT0WU
SK-MEL-3M2nJSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTZwNEK5NVUh|ryPNWTPR4oxW0GQR1XS
LB1047-RCCNF\yUY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn34TWM2OD14LkS3OlI2KM7:TR?=NITmNZZUSU6JRWK=
NCI-H446NY\KXpk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWPZSY4zUUN3ME22MlYzQTJ3IN88US=>NGnnS5lUSU6JRWK=
SW780MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlvwTWM2OD14LkewNVg2KM7:TR?=MnnDV2FPT0WU
NEC8NF3DWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2Ls[mlEPTB;Nj63OlY{KM7:TR?=NGrQZo9USU6JRWK=
NOMO-1Mmj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFTIRmxKSzVyPU[uO|gyOTFizszNNVPCdId6W0GQR1XS
COLO-668MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn3iTWM2OD14Lki0N|g4KM7:TR?=M17UcHNCVkeHUh?=
MC116MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{iwU2lEPTB;Nj65N|g6PyEQvF2=NETXS41USU6JRWK=
HCC1937NV\j[G91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTZwOUmyOVEh|ryPNHTjZXlUSU6JRWK=
NCI-N87M37pNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLvRo1KSzVyPUeuNVkzQTNizszNNX;YVlFbW0GQR1XS
COLO-320-HSRMlzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTdwMkK3N|gh|ryPMkHGV2FPT0WU
HCC1806M2H5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTdwMk[wOFQh|ryPM1HRUHNCVkeHUh?=
OVCAR-3M33v[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUHGOmpnUUN3ME23MlM{ODN6IN88US=>M1zBU3NCVkeHUh?=
NUGC-3MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYLV[Zk{UUN3ME23MlM6Pjl2IN88US=>NV35fIRUW0GQR1XS
SW1783M4Hmfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn35TWM2OD15LkSzNVc2KM7:TR?=NHLDdGFUSU6JRWK=
GCTNVy5ZnVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm[5TWM2OD15LkW2PVA3KM7:TR?=NYKyOpFGW0GQR1XS
NCI-H2126M2fieGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFPsTnVKSzVyPUeuO|M3OjVizszNMln2V2FPT0WU
MEL-HONIDxOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTdwN{ewOVQh|ryPMl:zV2FPT0WU
CAPAN-1Ml:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoXTTWM2OD15Lke3N|U4KM7:TR?=M1SxenNCVkeHUh?=
SW756M3jkTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGD4[W5KSzVyPUeuO|g{OzNizszNMV;TRW5ITVJ?
SKG-IIIaNFnXcmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnT0TWM2OD15LkixPFkzKM7:TR?=M2j6NXNCVkeHUh?=
HCE-TNVy4fow1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXnJT|M3UUN3ME23Mlg4Pzh|IN88US=>NY\JNFhpW0GQR1XS
Ca-SkiNYnUVVYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEC4RY1KSzVyPUeuPVk{QDNizszNMXfTRW5ITVJ?
COLO-684NVHRWnl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnzmTWM2OD16LkCxPFE5KM7:TR?=NVHEOVE2W0GQR1XS
KYSE-70Mm\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRThwMEe3Nlkh|ryPMnTrV2FPT0WU
TI-73MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVSyUVhjUUN3ME24MlI2QDVzIN88US=>MmezV2FPT0WU
BT-20M1;GNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvUPZlKSzVyPUiuNlYxPTJizszNMWnTRW5ITVJ?
MHH-ES-1MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1jBN2lEPTB;OD61NVg{PCEQvF2=MX3TRW5ITVJ?
TE-12NIfndnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml7QTWM2OD16LkW5PVMyKM7:TR?=NX7Ffm9qW0GQR1XS
YH-13NEKydWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NELLc4FKSzVyPUiuOlExODhizszNMXjTRW5ITVJ?
SF126MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYnJR|UxRThwOEO4OlUh|ryPMm\LV2FPT0WU
J82NF\OemxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnVZmhKSzVyPUiuPVAxOzhizszNNInCWllUSU6JRWK=
RCC10RGBMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHPwOlhKSzVyPUiuPVk2PjFizszNNVj2cVBZW0GQR1XS
SK-UT-1MmnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTlwMES5OFUh|ryPMo\JV2FPT0WU
LB2241-RCCNITXXXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTlwMUmxN|ch|ryPMoTWV2FPT0WU
LB996-RCCNVjvSmxET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnLnTWM2OD17LkG5PFkh|ryPMWPTRW5ITVJ?
EPLC-272HNFHkO4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;RV|JXUUN3ME25MlM4PjV5IN88US=>MVnTRW5ITVJ?
CTV-1NFTNZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkP1TWM2OD17LkW2OVMzKM7:TR?=NHvib|hUSU6JRWK=
HSC-2M373WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnT1TWM2OD17LkW3OVUh|ryPMmTFV2FPT0WU
SK-MEL-28NGDofGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1nPXGlEPTB;OT62NVg6OyEQvF2=M3znVHNCVkeHUh?=
MMAC-SFNVXsRZJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2f3XWlEPTB;OT62PFc2KM7:TR?=NUflNmp3W0GQR1XS
CP50-MEL-BMkHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlfBTWM2OD17Lke1O|gzKM7:TR?=NGjKSZZUSU6JRWK=
HT-1080M1HhNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLxbVdKSzVyPUmuO|c4OzlizszNM3rCUHNCVkeHUh?=
HEC-1M1H2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnjXTWM2OD1zMD6zN|UzKM7:TR?=M4LwfnNCVkeHUh?=
AGSM1ztemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3r0XmlEPTB;MUCuN|c1KM7:TR?=MmXDV2FPT0WU
GAMGNXqySIhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkTnTWM2OD1zMD61NVYzKM7:TR?=MX3TRW5ITVJ?
SW48NUfocFhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHHJ[lRKSzVyPUGwMlUyQDlizszNM3LsSXNCVkeHUh?=
U031MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX;NeZhzUUN3ME2xNE42QTB6IN88US=>NF2zc2NUSU6JRWK=
OVCAR-5MnLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnPXTWM2OD1zMD62OFI6KM7:TR?=M{CzTnNCVkeHUh?=
SF295Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHuWVJKSzVyPUGwMlY4ODRizszNM2PNfXNCVkeHUh?=
BHT-101NXnaZnh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4TaPWlEPTB;MUCuO|E4PyEQvF2=M37pVHNCVkeHUh?=
VMRC-RCZNHf6PVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLp[XpuUUN3ME2xNU4{OjBzIN88US=>MljYV2FPT0WU
ACHNNGT6[3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGfFRoRKSzVyPUGxMlQzOTFizszNMoqwV2FPT0WU
NCI-H526NGrvNllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXvmZ|FrUUN3ME2xNU42ODR|IN88US=>M13lVHNCVkeHUh?=
MN-60NFrhflJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFi3N5VKSzVyPUGxMlU{QSEQvF2=NI\K[W9USU6JRWK=
NCI-H2291MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2HPNWlEPTB;MUGuOVQ3PiEQvF2=Ml;hV2FPT0WU
SCC-25MknaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDaeWhSUUN3ME2xNU44PTV4IN88US=>Ml7iV2FPT0WU
SK-MEL-2MlT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTFzLke2N|ch|ryPMl;xV2FPT0WU
SN12CM2TiZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHj5UFdKSzVyPUGxMlk{PTVizszNMV7TRW5ITVJ?
NCI-H69M1m2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnq3TWM2OD1zMj60NlM1KM7:TR?=NV:xbZBQW0GQR1XS
ME-180MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX3ERoZkUUN3ME2xNk44ODV2IN88US=>M4fCO3NCVkeHUh?=
MC-IXCMljkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFr2OXRKSzVyPUGyMlc2OThizszNNY\JNGxHW0GQR1XS
NCI-H2347NEPaNWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTF{Lke2NVQh|ryPMoHrV2FPT0WU
M059JM2PIZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEDQcXpKSzVyPUGyMlc4OjdizszNMYLTRW5ITVJ?
A2058MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn;QTWM2OD1zMj64OlgyKM7:TR?=MYPTRW5ITVJ?
VA-ES-BJNX;UVFl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3S2emlEPTB;MUKuPFc5PSEQvF2=MoL4V2FPT0WU
Ca9-22M{P3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF3PXHlKSzVyPUGyMlk1PTFizszNMlfyV2FPT0WU
KNS-42NFi4S3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHfWcoVKSzVyPUGyMlk6QDRizszNM4HLWnNCVkeHUh?=
LoVoMoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jiWmlEPTB;MUOuNlMyOyEQvF2=NHfJfXJUSU6JRWK=
AM-38MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVywOYIzUUN3ME2xN{4zPTZ4IN88US=>NEPrVlFUSU6JRWK=
NB5MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUjM[3dxUUN3ME2xN{4{PzV{IN88US=>M3HyfnNCVkeHUh?=
L-363M3f2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTF|LkSwN|Mh|ryPNHywbINUSU6JRWK=
SK-MEL-30MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVK1RohOUUN3ME2xOE4xPjR3IN88US=>MX\TRW5ITVJ?
NCI-H1563M{Dafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTF2Lk[wN|kh|ryPM{fNeHNCVkeHUh?=
NCI-H2228NGTLbI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTF2Lk[wO|ch|ryPNF3vTJNUSU6JRWK=
MFM-223NEWwc2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWDweZdkUUN3ME2xOU4yQDF|IN88US=>NVv1TGFjW0GQR1XS
LB831-BLCMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFjoVJFKSzVyPUG1MlI4PjdizszNM{nVRnNCVkeHUh?=
SW872NYrEfItTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlP5TWM2OD1zNT6zNFg3KM7:TR?=NWTQSVVoW0GQR1XS
NCI-H522NHizNXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnLqTWM2OD1zNT6zN|A3KM7:TR?=MmX5V2FPT0WU
EW-1NVTSfmtYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTF3LkW0OlIh|ryPM{XRUHNCVkeHUh?=
HNMn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTF3LkW5OFIh|ryPM{HGcnNCVkeHUh?=
SW837MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\ITWM2OD1zNT63PFQ4KM7:TR?=MkfWV2FPT0WU
SCC-9MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1jmc2lEPTB;MUWuPFEyPCEQvF2=NX:1R2xwW0GQR1XS
MKN7M4G1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIPsV2xKSzVyPUG1Mlk4OzJizszNMk\LV2FPT0WU
KYSE-410M4nOO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\2TWM2OD1zNj61PVEh|ryPNYrWPHRDW0GQR1XS
SK-N-DZMn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTF4Lk[xNVYh|ryPM{Dj[XNCVkeHUh?=
COR-L105NGq5dnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVXSTo9YUUN3ME2xOk43PTJ6IN88US=>MULTRW5ITVJ?
LB2518-MELMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGroSYZKSzVyPUG2Mlg{QDlizszNM3LWU3NCVkeHUh?=
OVCAR-4M1rqemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIfjVHhKSzVyPUG2Mlg5PjJizszNMlzVV2FPT0WU
TK10M133TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTF4Lkm0O|Mh|ryPNFyxboZUSU6JRWK=
KNS-62NEfoWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYThSI1{UUN3ME2xOk46Pzd5IN88US=>MXrTRW5ITVJ?
RPMI-8866MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3Xxe2lEPTB;MUeuNVc{OiEQvF2=NUPZZ5N[W0GQR1XS
HuP-T4M4THSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG\ROmxKSzVyPUG3MlI1QTVizszNMon6V2FPT0WU
CGTH-W-1NXrpd5JPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV;JR|UxRTF5LkWyNVkh|ryPMXTTRW5ITVJ?
T-24NV;I[mRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTF5LkWzOFch|ryPMYLTRW5ITVJ?
HT-3MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfKTWM2OD1zNz61PVE1KM7:TR?=NEXudFhUSU6JRWK=
KS-1NF7GWVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTF5Lk[3N{DPxE1?NWfWRphwW0GQR1XS
NCI-H1792M2\1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrzNlNKSzVyPUG3Mlc6QCEQvF2=MXTTRW5ITVJ?
ABC-1NH:5XoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTF5LkixOFEh|ryPM3TEPHNCVkeHUh?=
BPH-1Ml65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTF6LkG2PFUh|ryPMmfnV2FPT0WU
A431NU\IdGJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2nzUmlEPTB;MUiuOFEzPyEQvF2=M37LdXNCVkeHUh?=
T98GMmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWrKXJNPUUN3ME2xPE42OTV5IN88US=>MULTRW5ITVJ?
BHYMl;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2rSVGlEPTB;MUiuPFY6KM7:TR?=MlzHV2FPT0WU
Capan-2MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnTsTWM2OD1zOD65NFc5KM7:TR?=M1PQV3NCVkeHUh?=
MDA-MB-175-VIIM3naVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG\SNYRKSzVyPUG4MlkzODlizszNNWjvOVJjW0GQR1XS
CAL-27MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTF7LkC0PFch|ryPMUHTRW5ITVJ?
AsPC-1MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXSzR41qUUN3ME2xPU45PjV5IN88US=>M3\0U3NCVkeHUh?=
KU812NV;hWZhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjvNXRKSzVyPUG5Mlk2PzNizszNMkTIV2FPT0WU
NCI-H441NFnOT|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWPHbJk5UUN3ME2yNE4xODFizszNMVzTRW5ITVJ?
MewoM{nwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrPUJRKSzVyPUKwMlEzQDhizszNMkfXV2FPT0WU
SK-MEL-24M3PzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLhTWM2OD1{MD6xOFc4KM7:TR?=MoruV2FPT0WU
NCI-H727NVrFSmU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVfBbms1UUN3ME2yNE4zPzB2IN88US=>NXvFV4NIW0GQR1XS
EKVXMln2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnLmTWM2OD1{MD62NFYh|ryPM2DSfXNCVkeHUh?=
RT-112NVi1fZNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPsTWM2OD1{MD62NVIzKM7:TR?=M1XkS3NCVkeHUh?=
CAMA-1NFHlVoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkL5TWM2OD1{MD65PFA{KM7:TR?=M3P4Z3NCVkeHUh?=
SW900NUfvdG56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1f4XWlEPTB;MkGuNFE1QSEQvF2=MUjTRW5ITVJ?
NCI-H23NVTMV2F{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17Xc2lEPTB;MkGuNVI4PyEQvF2=Mnv4V2FPT0WU
SK-PN-DWMl61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoHVTWM2OD1{MT6xOlQ6KM7:TR?=MnG1V2FPT0WU
BB30-HNCNUXlcph3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2rxN2lEPTB;MkGuNlc1PSEQvF2=M2Tpc3NCVkeHUh?=
VM-CUB-1MlT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTJzLkO1N|Yh|ryPM3y1SXNCVkeHUh?=
IST-MEL1MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4nqXmlEPTB;MkGuN|Y6OiEQvF2=M{XRPXNCVkeHUh?=
CTB-1MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M37IUGlEPTB;MkGuOFc2PSEQvF2=NWHmNpZzW0GQR1XS
LCLC-103HMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIrIXmNKSzVyPUKyMlE2QDJizszNNYTWOmE6W0GQR1XS
PANC-03-27MkfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2LJbGlEPTB;MkKuOVE3QSEQvF2=Ml\IV2FPT0WU
HTC-C3Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTJ{LkW1OVUh|ryPM1y4RnNCVkeHUh?=
TE-8NX7MRWxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXvtR3ZKUUN3ME2yN{4zPTZ3IN88US=>MVLTRW5ITVJ?
NCI-H292MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVfFNWJsUUN3ME2yOU4{PTN4IN88US=>NF7Dd4tUSU6JRWK=
COLO-680NM{Xy[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\RXItKSzVyPUK1MlY{OjlizszNNILYNIpUSU6JRWK=
KYSE-520Ml\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXHJR|UxRTJ3Lk[0OEDPxE1?Mn;VV2FPT0WU
NB10NF62bFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEfXWnJKSzVyPUK2MlMyOTdizszNMUfTRW5ITVJ?
NCI-H661MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjVeI9jUUN3ME2yOk41PzF|IN88US=>NVPifYNHW0GQR1XS
GMS-10NH[0cYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWC3[IVuUUN3ME2yOk45PjN6IN88US=>M1:wd3NCVkeHUh?=
NCI-H2122MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NI\IWmdKSzVyPUK2Mlk6QThizszNMnz2V2FPT0WU
OVCAR-8MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVqyd|J4UUN3ME2yO{4xPjN6IN88US=>M{npOXNCVkeHUh?=
DJM-1NWDkcWlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{DFbWlEPTB;MkeuNVQ2PCEQvF2=NIrDb5pUSU6JRWK=
UACC-893NV2yfIkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTJ5Lkm4O|gh|ryPNF33OZVUSU6JRWK=
C8166NIq5[|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIO5UmJKSzVyPUK4MlY6OzhizszNMnTiV2FPT0WU
NCI-H1693NVv4b3ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTJ6Lk[5O|Uh|ryPNGDFc3JUSU6JRWK=
TYK-nuNV76eVlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2X1dWlEPTB;M{CuNFM1PSEQvF2=NETS[2lUSU6JRWK=
SW1710MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHW4OYtKSzVyPUOwMlEzPiEQvF2=NVv5eIZrW0GQR1XS
A375M2DQNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXfJR|UxRTNyLkOyOFMh|ryPM3T1VHNCVkeHUh?=
HMV-IIM1\sd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIPOd5dKSzVyPUOxMlM2QTJizszNNFTmXGtUSU6JRWK=
NCI-H2087NFzSSVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmLGTWM2OD1|MT62N|UzKM7:TR?=Mo\JV2FPT0WU
CAL-54MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1ixSmlEPTB;M{GuO|I1OSEQvF2=MknvV2FPT0WU
HCC70MnLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVHJR|UxRTN{LkGzPFch|ryPNHTUXIxUSU6JRWK=
ES1MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\QTWM2OD1|Mj6zNFYzKM7:TR?=NIHjeWxUSU6JRWK=
NCI-H1355MkLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmixTWM2OD1|Mz6yNFQh|ryPMkH4V2FPT0WU
CFPAC-1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIThbYxKSzVyPUOzMlI{OzJizszNMmPZV2FPT0WU
MKN28MlTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1u4OWlEPTB;M{OuN|gxQSEQvF2=MYXTRW5ITVJ?
HDLM-2NGPtWFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4LueGlEPTB;M{OuOlk{OSEQvF2=M{fHZXNCVkeHUh?=
PANC-10-05NYnW[2RwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{nvc2lEPTB;M{SuNVAyPCEQvF2=MX3TRW5ITVJ?
SASNXSyW4RnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHK2PG1KSzVyPUO0MlQ2PjVizszNNHTPcoxUSU6JRWK=
HCC1395NV;KdnBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTHTWM2OD1|ND63NVg3KM7:TR?=MV7TRW5ITVJ?
8305CMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTN3Lki0NVUh|ryPNY\zPYxwW0GQR1XS
KM12NWL0eXpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFGzRoRKSzVyPUO2Mlc2PDdizszNMnzFV2FPT0WU
SW1116MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmTiTWM2OD1|Nz61PVkzKM7:TR?=NUSwWoV[W0GQR1XS
SK-MEL-1NHXCc2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTN6LkOzPFkh|ryPNHLCUVVUSU6JRWK=
HCC2218M4TVNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTN6Lk[1NVkh|ryPNFfoVldUSU6JRWK=
T84MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mlz4TWM2OD1|OD63OFA6KM7:TR?=M{fG[nNCVkeHUh?=
ETK-1MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\RXWlEPTB;M{muNFIzKM7:TR?=MUDTRW5ITVJ?
COLO-800MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4X4XWlEPTB;M{muN|g3QCEQvF2=MlLpV2FPT0WU
CAL-12TNF7VZ3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnnLTWM2OD1|OT61NlgyKM7:TR?=M4rQeXNCVkeHUh?=
ACNNUjkWZBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWTlW4s{UUN3ME20NE41QTFzIN88US=>MYrTRW5ITVJ?
SJSA-1NETxN2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXfJR|UxRTRzLkG1PVYh|ryPNVTxVWxjW0GQR1XS
PSN1NGrzXXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV;JR|UxRTRzLkG3OFkh|ryPMnu5V2FPT0WU
D-566MGM2LJVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTRzLkKwPFYh|ryPMUnTRW5ITVJ?
EGI-1MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTR{LkSyPEDPxE1?NH;SXXZUSU6JRWK=
A204MoflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVHJR|UxRTR{Lk[zPFgh|ryPNYXvcmVKW0GQR1XS
Saos-2NFHnVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYj2OndmUUN3ME20Nk45OzZ7IN88US=>MnHuV2FPT0WU
SNU-C2BMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTR|Lk[4O|gh|ryPNVTjc4hCW0GQR1XS
HLEM1;PN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmqxTWM2OD12ND6wPFU3KM7:TR?=NITNN5NUSU6JRWK=
SW1463NI\3SIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlGwTWM2OD12ND65PVcyKM7:TR?=MUDTRW5ITVJ?
DSH1M4nkVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDGTWM2OD12NT6wNFM{KM7:TR?=MlTKV2FPT0WU
MCF7NVfmUGtZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFG4Vm9KSzVyPUS1MlUxPTFizszNNIjpW|dUSU6JRWK=
K5NYj0d|dxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33RdmlEPTB;NEWuPVQxPSEQvF2=MlnEV2FPT0WU
NCI-H358NHLsNnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH;IeolKSzVyPUS3MlIyPSEQvF2=NEL6RYJUSU6JRWK=
NCI-H2030M4G2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MorRTWM2OD12Nz6yN|c1KM7:TR?=M4[0UHNCVkeHUh?=
SW948NGH5S|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUf4O284UUN3ME20O{41PjRizszNMmnqV2FPT0WU
BALL-1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M122[WlEPTB;NEeuOlE3QCEQvF2=NW\tSoFWW0GQR1XS
TE-9M37TVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XtdWlEPTB;NEeuPVU5OSEQvF2=M3XmenNCVkeHUh?=
SK-N-FIMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIn6OHlKSzVyPUS4MlA{PThizszNM1HHVnNCVkeHUh?=
KALS-1M1:xN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYSzcHRPUUN3ME20PE4yOjh7IN88US=>NFjQfXdUSU6JRWK=
HO-1-N-1M{W4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M330WmlEPTB;NEiuO|Q1PSEQvF2=MnTmV2FPT0WU
NCI-H2452NWPMdFhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fnZWlEPTB;NEmuNVE2OiEQvF2=MkLsV2FPT0WU
OC-314NYDOcpU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1nhOGlEPTB;NEmuOlg{PCEQvF2=NEDnfJZUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

Affinity determination Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.

Cell Assay:

[1]

Cell lines SCLC cell lines
Concentrations 0-1 μM
Incubation Time 48 hours
Method

Human tumor cell lines SCLC cell lines are maintained at 37 °C containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.

Animal Study:

[1]

Animal Models C.B.-17 scid-bg or C.B.-17 scid mice
Formulation Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
Dosages 100 mg/kg/d
Administration Administered via p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Tse C, et al. Cancer Res. 2008, 68(9), 3421-3428.

[2] Shoemaker AR, et al. Clin Cancer Res, 2008, 14(11), 3268-3277.

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02520778 Recruiting Recurrent Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Ca  ...more Recurrent Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer National Cancer Institute (NCI) March 2016 Phase 1
NCT02591095 Recruiting Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Canc  ...more Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02143401 Recruiting Recurrent Hepatocellular Carcinoma|Solid Neoplasm|Stage IV Hepatocellular Carcinoma National Cancer Institute (NCI) November 2014 Phase 1
NCT02079740 Suspended Recurrent Colorectal Carcinoma|Recurrent Lung Carcinoma|Recurrent Pancreatic Carcinoma|Solid Neoplasm|Stage III Lung Cancer|Stage III Pancreatic Ca  ...more Recurrent Colorectal Carcinoma|Recurrent Lung Carcinoma|Recurrent Pancreatic Carcinoma|Solid Neoplasm|Stage III Lung Cancer|Stage III Pancreatic Cancer|Stage IIIA Colorectal Cancer|Stage IIIB Colorectal Cancer|Stage IIIC Colorectal Cancer|Stage IV Lung Cancer|Stage IV Pancreatic Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer National Cancer Institute (NCI) March 2014 Phase 1|Phase 2
NCT01989585 Recruiting Metastatic Melanoma|Recurrent Melanoma|Solid Neoplasm|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Mela  ...more Metastatic Melanoma|Recurrent Melanoma|Solid Neoplasm|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma National Cancer Institute (NCI) October 2013 Phase 1|Phase 2

view more

Chemical Information

Download ABT-263 (Navitoclax) SDF
Molecular Weight (MW) 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 100 mg/mL (102.6 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 5% DMSO+corn oil 7mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-​[4-​[[2-​(4-​chlorophenyl)​-​5,​5-​dimethyl-​1-​cyclohexen-​1-​yl]​methyl]​-​1-​piperazinyl]​-​N-​[[4-​[[(1R)​-​3-​(4-​morpholinyl)​-​1-​[(phenylthio)​methyl]​propyl]​amino]​-​3-​[(trifluoromethyl)​sulfonyl]​phenyl]​sulfonyl]​-benzamide

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Bcl-2 Products

  • A-1210477

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

    Features:Re-engineered version of ABT-263 (Navitoclax).

  • ABT-737

    ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

  • UMI-77

    UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.

  • Obatoclax Mesylate (GX15-070)

    Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

    Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

  • TW-37

    TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.

  • Sabutoclax

    Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.

  • AT101

    AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Recently Viewed Items

Tags: buy ABT-263 (Navitoclax) | ABT-263 (Navitoclax) supplier | purchase ABT-263 (Navitoclax) | ABT-263 (Navitoclax) cost | ABT-263 (Navitoclax) manufacturer | order ABT-263 (Navitoclax) | ABT-263 (Navitoclax) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us